Updated: Mar 4
Aarogyam (UK), University of Warwick and Jodhpur Ayurveda University have joined forces to support mild-to-moderate community-based patients in the UK.
The CBPR trial aims to respond to the urgent need to identify feasible treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalization that could overwhelm fragile and already overburdened health systems in the UK.
The feasibility trial has been carried out with community organizations, coordinated
by the Aarogyam (UK). CBPR feasibility trial comparative, ‘adaptive trial’ that tested the safety and efficacy of Ayurveda combinations (ashwagandha, Giloy and Tulsi) in mild-to-moderate COVID-19 patients has found that early Ayurveda intervention can prevent progression of COVID-19 to severe disease and potentially accelerate recovery.
Warwick University Researchers led by Dr Vishwesh Kulkarni, not only found clinical efficacy data but also tested treatment outcome through machine learning and Artificial Intelligence methods. New methods to test interventions has been added to the study as evidence of their potential for mild-to-moderate cases emerges. UK researchers are actively looking to select the most promising treatments from ongoing global scientific efforts with proof of efficacy, incollaboration with the Jodhpur Ayurveda University, India.
“‘The Aarogyam consortium is a broad partnership bringing UK scientific leaders and India experts of Ayurveda together to respond to an urgent unmet medical need.Collaboration is the only way to provide robust scientific responses to these research questions”